Next-Generation Antibiotics Conferences | Europe | Asia | Middle East | Canada | Japan | Australia | USA

Next-Generation Antibiotics

Next-generation antibiotics are innovative antimicrobial agents designed to combat multidrug-resistant (MDR) bacteria that no longer respond to conventional therapies. These advanced treatments employ novel mechanisms of action, including targeting bacterial virulence factors, microbiome modulation, and precision antimicrobial approaches, to improve treatment outcomes while addressing the growing threat of antimicrobial resistance (AMR). This session will explore recent advances in antibiotic discovery, novel therapeutics, resistance mechanisms, and strategies to combat drug-resistant infections.

Market Analysis:
The global next-generation antibiotics market is experiencing strong growth, driven by the rising burden of antimicrobial resistance, increasing investment in antibiotic research, and supportive regulatory initiatives. As of 2026, the market is estimated at approximately USD 6 billion and is projected to exceed USD 10.5 billion by 2031, growing at a CAGR of around 12%. North America remains the leading market due to robust R&D and favorable funding, while the Asia-Pacific region is expected to witness the fastest growth, supported by expanding healthcare infrastructure and increasing efforts to address antimicrobial resistance.

Tracks